Role of Intraoperative Beta Blocker for Morbid Obese Patients Undergoing Laparoscopic Bariatric Surgery

Postoperative Pain Clinical Trial

Official title:

Lecturer of Anesthesia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04086940
• Other study ID #: Ain Shams university 1
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: November 2019
• Est. completion date: December 2019

Study information

• Verified date: November 2019
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Using esmolol during anesthetic maintenance of laparoscopic bariatric surgery significantly decreases anesthetic, analgesic requirements, postoperative pain, PNV and postoperative hypoxia.

Description:

Postoperative pain, nausea, vomiting (PNV) and hypoxia are common in relation to laparoscopic bariatric surgery. Sympatholytic drugs might decrease the need for intravenous or Inhalation anesthetics and opioids. In this study we wanted to analyze effects of esmolol on intraoperative anesthetic-analgesic requirements, postoperative analgesic requirements, postoperative pain, PNV and hypoxia.

Methods: Sixty patients have been included. Propofol, fentanyl and rocuronium were used for induction. Study groups were as follows; group E Esmolol infusion was added to maintenance anesthetics (Sevoflurane and fentanyl), group N only Sevoflurane and fentanyl was used during maintenance. They have been monitored during the intraoperative period and postoperatively for 24 h for analgesic requirements and PNV. Visual analog scale (VAS) scores for pain was also been assessed.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: December 2019
• Est. primary completion date: November 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 59 Years

Eligibility

Inclusion Criteria:

• American Society of Anesthesiologists (ASA) I - II patients

• age between 18-59 years

• both genders

• body mass index (BMI) > 45 kg/m2

Exclusion Criteria:

• Patients with -hepatic

• renal

• cardiac

• respiratory diseases

• patients with a history of drug abuse or who were dependent on opioid drugs.

Related Conditions & MeSH terms

• Intraoperative Awareness
• Postoperative Pain

Intervention

Drug:
• Esmolol
preventive

Locations

Country	Name	City	State
Egypt	Ramymahrose	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	intraoperative analgesic requirements	amount of narcotics and anesthetics needed	6 months
Primary	postoperative analgesic requirements	amount of narcotics needed	6 months